Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.52 |
| ▸ | GMNN | O75496 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | THPO | P40225 | 1/20 | 0.52 |
| ▸ | MTOR | P42345 | 1/20 | 0.52 |
| ▸ | BLM | P54132 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | CETP | P11597 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | UBE2N | P61088 | 1/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL940984 | 1.00 | CYP2D6 (0.52) | CYP2D6LMNASPHK1GMNNPOLB | |
| SCHEMBL1499941 | 1.00 | CYP2D6 (0.52) | CYP2D6LMNASPHK1GMNNPOLB | |
| SCHEMBL1068428 | 1.00 | CYP2D6 (0.52) | CYP2D6LMNASPHK1GMNNPOLB | |
| SCHEMBL4105974 | 1.00 | CYP2D6 (0.52) | CYP2D6LMNASPHK1GMNNPOLB | |
| SCHEMBL2015033 | 1.00 | CYP2D6 (0.52) | CYP2D6LMNASPHK1GMNNPOLB | |
| SCHEMBL1064522 | 1.00 | CYP2D6 (0.52) | CYP2D6LMNASPHK1GMNNPOLB | |
| SCHEMBL8502257 | 1.00 | CYP2D6 (0.52) | CYP2D6LMNASPHK1GMNNPOLB | |
| SCHEMBL9070449 | 1.00 | CYP2D6 (0.52) | CYP2D6LMNASPHK1GMNNPOLB | |
| SCHEMBL2305353 | 0.98 | LMNA (0.48) | CYP2D6LMNASPHK1GMNNPOLB | |
| SCHEMBL9167639 | 0.93 | CYP2D6 (0.46) | CYP2D6LMNASPHK1GMNNPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040208783-A1 | Process for the chemical and thermal disinfection | AIR LIQUIDE SANTE (INTERNATIONAL ) (FR) | 2004-10-21 | — | — | US | claimed |
| EP-1468606-A1 | Process for the chemical and thermal disinfection | Air Liquide Santé (International) (FR) | 2004-10-20 | — | — | EP | claimed |
| US-20030045676-A1 | Peptides, antibodies, vaccines & uses thereof | KINGSTON DAVID J (AU) | 2003-03-06 | — | — | US | claimed |
| US-20020187925-A1 | Modulating the activity of hormones or their receptors - peptides, antibodies, vaccines and uses thereof | KINGSTON DAVID J (AU) | 2002-12-12 | — | — | US | claimed |
| US-20020169116-A1 | Modulating the activity of hormones or their receptors - peptides, antibodies, vaccines and uses thereof | KINGSTON DAVID J (AU) | 2002-11-14 | — | — | US | claimed |
| JP-62258731-A | — | — | None | — | — | JP | disclosed |
| CN-102040621-B | Lipid oxide and the application in treatment inflammatory diseases thereof | CANALIS-HAEMALIS BIOGROWTH LTD. (IL) | 2016-01-20 | — | — | CN | disclosed |
| CN-104602709-A | Novel HA binding reagents | VISTERRA INC | 2015-05-06 | — | — | CN | disclosed |
| US-8563534-B2 | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis | VASCULAR BIOGENICS LTD. (IL) | 2013-10-22 | — | — | US | disclosed |
| US-8501715-B2 | Oxidized lipids and uses thereof in the treatment of inflammatory diseases and disorders | VASCULAR BIOGENICS LTD. (IL) | 2013-08-06 | — | — | US | disclosed |
| EP-1626728-B1 | OXIDIZED LIPIDS AND USES THEREOF IN THE TREATMENT OF INFLAMMATORY DISEASES AND DISORDERS | VASCULAR BIOGENICS LTD (IL) | 2013-07-10 | — | — | EP | disclosed |
| US-20120329757-A1 | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis | VASCULAR BIOGENICS LTD. (IL) | 2012-12-27 | — | — | US | disclosed |
| US-20020107187-A1 | Modulating the activity of hormones or their receptors - peptides, antibodies, vaccines and uses thereof | KINGSTON DAVID J (AU) | 2002-08-08 | — | — | US | disclosed |
| WO-2002041827-A2 | METHODS EMPLOYING AND COMPOSITIONS CONTAINING DEFINED OXIDIZED PHOSPHOLIPIDS FOR PREVENTION AND TREATMENT OF ATHEROSCLEROSIS | VASCULAR BIOGENICS LTD. (IL) | 2002-05-30 | — | — | WO | disclosed |
| EP-0781780-B1 | Polysaccharide derivative, and preparation process and use thereof | KAO CORP (JP) | 2002-05-29 | — | — | EP | disclosed |
| EP-1012171-A1 | MODULATING THE ACTIVITY OF HORMONES OR THEIR RECEPTORS - PEPTIDES, ANTIBODIES, VACCINES AND USES THEREOF | Northstar Biologicals Pty. Ltd. (AU) | 2000-06-28 | — | — | EP | disclosed |
| US-5891450-A | Polysaccharide derivative, and preparation process and use thereof | KAO CORPORATION (JP) | 1999-04-06 | — | — | US | disclosed |
| WO-1997044352-A1 | MODULATING THE ACTIVITY OF HORMONES OR THEIR RECEPTORS - PEPTIDES, ANTIBODIES, VACCINES AND USES THEREOF | NORTHSTAR BIOLOGICALS PTY. LTD. (AU) | 1997-11-27 | — | — | WO | disclosed |
| EP-0781780-A2 | Polysaccharide derivative, and preparation process and use thereof | Kao Corporation (JP) | 1997-07-02 | — | — | EP | disclosed |
| JP-S62258731-A | OIL-IN-WATER-TYPE EMULSIFIED COMPOSITION | KAO CORP | 1987-11-11 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120329757-A1 | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis | PHOSPHO1, GPX4, SGMS1 | CYP2D6 2668/4885LMNA 1687/4885SPHK1 266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.